Cost-effectiveness analysis of nivolumab plus ipilimumab <i>versus</i> chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma.

导出 OA

翻译打印收藏纠错

第一作者： Liu,Yang

第一单位： Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.

作者： Liu,Yang ^[1] ; Xueqiong,Cao ^[1] ; Na,Li ^[1] ; Bin,Zheng ^[1] ; Maobai,Liu ^[2] ; Hongfu,Cai ^[2]

作者单位： Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China. ^[1] Department of Pharmacy, Fujian Medical University Union Hospital, Fujian Medical University, Xinquan Road 29, Fuzhou 350100, China. ^[2]

关键词 cost-effectiveness first-line treatment ipilimumab malignant pleural mesothelioma nivolumab

DOI 10.1177/17588359221116604

PMID 35958872

发布时间 2022-08-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Therapeutic advances in medical oncology

2022年14卷

17588359221116604页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Cost-effectiveness analysis of nivolumab plus ipilimumab <i>versus</i> chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Cost-effectiveness analysis of nivolumab plus ipilimumab <i>versus</i> chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

检索历史清除